3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Endocrine
1
Conditions
Breast Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Breast Diseases
1
Advanced Metastatic Breast Cancer
1
Interventions
Trastuzumab
9
Capecitabine
7
trastuzumab deruxtecan
6
Paclitaxel
6
Fulvestrant
6
pertuzumab
5
eribulin
5
Gemcitabine
4
Cyclophosphamide
4
sacituzumab govitecan
3
Vinorelbine
3
Doxorubicin
3
Docetaxel
3
Ado-Trastuzumab Emtansine
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
palbociclib
2
olaparib
2
larotrectinib
2
exemestane
2
abemaciclib
2
Fluorouracil
2
Epirubicin
2
Carboplatin
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
taxane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Breast Neoplasms
×
ribociclib
×
Clear all
NCT03701334
2026-04-01
NATALEE
Novartis
Phase 3
Active not recruiting
5,101 enrolled
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA